INVESTOR DEADLINE: Soleno Therapeutics Inc. (SLNO) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RGRD Law

AI Briefing

• – Investors affected by alleged downplaying of safety concerns in Soleno Therapeutics Inc. (SLNO) Phase 3 clinical trial program.
• – Class action lawsuit seeks damages for misrepresented information.
• – Investors with substantial losses have opportunity to participate in lawsuit.